All News

Article

EULAR 2019 Report – Day 2

Jack Cush, MD Jun 13, 2019

It was a full and lively 2nd day in Madrid with sessions dedicated to Lupus, RA, Sjogren’s, imaging, rare diseases, psoriatic arthritis and spondyloarthritis. Here are a few of the highlights from day 2 EULAR in Madrid

GCA patients have decreased proportions of PD1+CD4+ Th cells compared to normal controls, building on previous Weyand lab work. Once again, irAEs and PMR/GCA might be friends? #EULAR2019 FRI0266 Hid Cadena from Elisabeth Brouwer’s group @RheumNow https://t.co/H6bhO1jH2S

Mayo RCT on Flares in established RA randomized 150 pts to usual care or a flare (pt self declared) survey scheme found pts flaring prefer self management 62% over expedited clinic visit 32%, but intervention was no better than usual care! OP0309 #Eular2019 https://t.co/zGlW43ppqi

Beautifully presented abstract on protective effect of LLDAS independent of baseline disease activity&damage status. Protection is higher in pts with active disease (SLEDAI >=6) and those already had damage accrual (SDI>=1). #eular2019 #aplc @EricFMorand @Monash_FMNHS @RheumNow

Performance of ACR CRISS in different recent trials. Superior to mRSS.#EULAR2019. @RheumNow https://t.co/giQEiFd0Uv

Central and peripheral site readers of SI joint MRIs - how do they fare in the nr-axSpA era? #EULAR2019 THU0359 from ASAS @RheumNow https://t.co/9RI22Gb7jx

Clinical practice-friendly VAS assessIng different aspects of Rheum diseases: physicians rated #gout inflammation, damage, and global scores as high/higher than RA. Dr Nika discusses. Let’s have high levels of gout treat-to-target strategy discussions too! @RheumNow #EULAR2019 https://t.co/wMf7yR2GPA

Does age of onset of Sjögren's syndrome change % with sicca symptoms (dry eyes & mouth)? #EULAR2019 @RheumNow

a few presentations from RISE-SSc at #EULAR2019. @BayerPharma @RheumNow 1. Riociguat has a beneficial impact on FVC. More data to support anti fibrotic role in early scleroderma ILD https://t.co/77SP2qU7SH

bilateral or unilateral knee inflammatory arthritis fully resolves in 60% at 1 yr. 10% spread. THU0674 #EULAR2019 @RheumNow https://t.co/lCjQ1aAvNz

OPO315 ERA cohort shows fatigue improvement lags behind remission by 6 months. #EULAR2019 @RheumNow https://t.co/6toBquAy2Q

Calcific rotator cuff tendonitis is usually treated with steroid injections and only 10% need surgery THU0504 #EULAR2019 @RheumNow https://t.co/VHBGJ36MlL

Initial prescription of #tramadol associated with > mortality vs #nsaids over 1 year follow up #EULAR2019 https://t.co/moBAohdkBx

Evan Vista posted on LinkedIn

Riociquat in Scleroderma ILD. Almost worked on skin, but did work in those with ILD. OP0183 #EULAR2019 https://t.co/ySHQxOCrb5

https://youtu.be/AGCa1MTbYg8

I hate the term “appropriate.” It’s meaningless or stands as a flag for moral/social/radical and cultural prejudice. Same with “rude.” So interpret it however you want.

Six weeks of low-dose prednisolone improved #Pain and function in hand #osteoarthritis according to data presented at #EULAR19 https://t.co/SKndJfojFw

Six weeks of low-dose prednisolone improved pain, function in hand OA

2019 EULAR/ACR #lupus #classification #criteria #EULAR19 https://t.co/PzuFUNgCs5

The always eloquent Raashid Luqmani holds a full plenary hall entranced with an AAV masterclass #EULAR2019 SP0044 @RheumNow https://t.co/sJ97QswXOY

Free Special Article in both A&R/AC&R #EULAR19 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non‐Systemic Polyarthritis, Sacroiliitis, and Enthesitis https://t.co/Ymu64QhV1G https://t.co/9vwfb5CWbZ

https://onlinelibrary.wiley.com/doi/10.1002/art.40884

Schulert, et al showed some beautiful work dissecting what drives monocytes and macrophages to go berzerk during Macrophage Activation Syndrome. Via transcriptional profiling, they find TRIM8 (E3 upiquitinligase) drives excessive IFNγ & is elevated in sJIA pts #EULAR2019 OP0150 https://t.co/A7ziCjcGhC

Topics

All News

EULAR 2019 Report – Day 2

Do you get our email newsletter?